Company Directory - Research & Development

Adicet is a biotechnology company engaged in the development of first-in-class off-the-shelf allogeneic gamma delta T cell therapies for cancer and other diseases.

AdoRx Therapeutics is a UK-based drug discovery company and backed by investment from Epidarex Capital and Sixth Element Capital. AdoRx Therapeutics is pursuing the discovery of new therapeutics for cancer-based on modulation of the adenosine pathway. High levels of adenosine in the tumour microenvironment enable cancer to evade the immune system.

Adrestia is developing therapeutics that work in an entirely new way – restoring the biological balance in damaged, diseased or dying cells. We are searching for novel therapies that suppress or over-ride these harmful pathways and keep cells healthy. It’s a concept known as synthetic viability.

The purpose of Agilent Research Laboratories is to power Agilent’s growth through breakthrough science and technology.

Akari Therapeutics was established in 2005 in the UK. We develop life-transforming treatments for autoinflammatory diseases involving the complement (C5) and leukotriene (LTB4) pathways.

Alacris Theranostics GmbH is a Berlin-based company founded in 2008 by pioneers in the fields of technology development, genomics, new generation sequencing applications and systems biology. The company’s core technologies have been in continuous development since 2000.

At Alchemab, we are harnessing the power of our immune system to cure disease. We turn drug discovery on its head by using nature’s most effective search engine: adaptive immunity. We identify “elite controllers” – or especially resilient individuals – and learn how they overcome or resist disease.

Alcresta develops novel products that deliver enzymatic solutions to those living with rare diseases. Based in Massachusetts, we have achieved significant commercial milestones, created an extensive intellectual property portfolio, optimized production capabilities, and developed exciting scientific data supporting its products and technology platform.

Alcyomics is a Newcastle based unique pre-clinical service provider using Skimune®, non-artificial human skin explants for predicting adverse immune reactions as well as determining efficacy of novel compounds including pharmaceuticals, chemicals and cosmetics.

We are a clinical-stage company developing therapeutic antibodies for inhibitory receptors on the surface of immune effector cells involved in allergic, inflammatory, and proliferative diseases.

We are a market leading, pioneering immunology business with specialist experience in the research and development of allergy treatments. We believe that transformational outcomes for patients are achieved by directly treating the cause, rather than just managing symptoms.

The Almac Group is an established contract development and manufacturing organisation providing an extensive range of integrated services across, and beyond, the drug development lifecycle to the pharmaceutical and biotech sectors globally.

Almirall is a leading skin-health focused global pharmaceutical company that partners with healthcare professionals, applying science to provide medical solutions to patients and future generations. Our efforts are focused on fighting skin health diseases and helping people feel better.

Amarna Therapeutics is a privately held Biotech company founded in 2008. Its head office is located in Leiden (The Netherlands), and its research facility in Seville (Spain).

Amicus Therapeutics (Nasdaq:FOLD) is a global, patient-dedicated biotechnology company focused on discovering, developing and delivering high-quality medicines for people living with rare metabolic diseases.

AnaptysBio is a clinical-stage biotechnology company developing first-in-class immunology therapeutic product candidates to patients. We are focused on emerging immune control mechanisms applicable to inflammation and immuno-oncology indications.

Antibody Analytics are specialists in primary cell method development and analysis, dedicated to advancing drug development. From discovery to the later clinical stages, we know how to build the correct assay designs at the appropriate stage to provide meaningful information to you and your team.

Antikor Ltd is a newly established company that is exploiting a novel technology platform called OptiLinked-FDCs, to generate revolutionary products to treat solid cancers. We are a multidisciplinary spin-out from Imperial College London UK now based at the Stevenage Bioscience Catalyst.

Antisense Therapeutics is an Australian publicly-listed biotechnology company, developing and commercializing antisense pharmaceuticals for large unmet markets in rare diseases. The products are in-licensed from Ionis Pharmaceuticals Inc. (NASDAQ: IONS), an established leader in antisense drug development.

At Apellis, we are committed to developing transformative therapies for people living with a broad range of debilitating diseases by controlling complement, part of the body’s immune system. Our work is rooted centrally at C3, which is the only target in the complement cascade that addresses all three pathways that can drive disease.